ArticleThe Journal of infectious diseases2014
Engineering, expression in transgenic plants and characterisation of E559, a rabies virus-neutralising monoclonal antibody.
Article in The Journal of infectious diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 55 citations in OpenAlex.
- Plant-based production and characterization of monoclonal antibodies targeting extracellular enveloped proteins of the Mpox Virus.Biotechnology reports (Amsterdam, Netherlands) · 2026Article
- Monoclonal antibodies in veterinary antiviral immunotherapy: technologies, applications and challenges.Veterinary research communications · 2025Review
- Exploring recent progress of molecular farming for therapeutic and recombinant molecules in plant systems.Heliyon · 2024Review
- Green Biologics: Harnessing the Power of Plants to Produce Pharmaceuticals.International journal of molecular sciences · 2023Review
- Efficiency Comparative Approach of Plant-Produced Monoclonal Antibodies against Rabies Virus Infection.Vaccines · 2023Article
- Characterisation of a Live-Attenuated Rabies Virus Expressing a Secreted scFv for the Treatment of Rabies.Viruses · 2023Article
- Killer to cure: Expression and production costs calculation of tobacco plant-made cancer-immune checkpoint inhibitors.Plant biotechnology journal · 2023Article
- Multiple gene expression in plants using MIDAS-P, a versatile type II restriction-based modular expression vector.Biotechnology and bioengineering · 2022Article
- Engineering theFrontiers in plant science · 2022Article
- Contributions of the international plant science community to the fight against infectious diseases in humans-part 2: Affordable drugs in edible plants for endemic and re-emerging diseases.Plant biotechnology journal · 2021Review
- Enhanced Ability of Plant-Derived PGT121 Glycovariants To Eliminate HIV-1-Infected Cells.Journal of virology · 2021Article
- Potential for Developing Plant-Derived Candidate Vaccines and Biologics against Emerging Coronavirus Infections.Pathogens (Basel, Switzerland) · 2021Review
- Review
- Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana.Scientific reports · 2020Article
- Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production.Plants (Basel, Switzerland) · 2020Review
- Article
- Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development.Pathogens (Basel, Switzerland) · 2020Review
- Monoclonal Antibodies B38 and H4 Produced inFrontiers in plant science · 2020Article
- Development of a minigenome cassette for Lettuce necrotic yellows virus: A first step in rescuing a plant cytorhabdovirus.PloS one · 2020Article
- Shotguns vs Lasers: Identifying barriers and facilitators to scaling-up plant molecular farming for high-value health products.PloS one · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 3 countries.
Funding
Abstract
Rabies post-exposure prophylaxis (PEP) currently comprises administration of rabies vaccine together with rabies immunoglobulin (RIG) of either equine or human origin. In the developing world, RIG preparations are expensive, often in short supply, and of variable efficacy. Therefore, we are seeking to develop a monoclonal antibody cocktail to replace RIG. Here, we describe the cloning, engineering and production in plants of a candidate monoclonal antibody (E559) for inclusion in such a cocktail. The murine constant domains of E559 were replaced with human IgG1κ constant domains and the resulting chimeric mouse-human genes were cloned into plant expression vectors for stable nuclear transformation of Nicotiana tabacum. The plant-expressed, chimeric antibody was purified and biochemically characterized, was demonstrated to neutralize rabies virus in a fluorescent antibody virus neutralization assay, and conferred protection in a hamster challenge model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.